Columnist Dagmar Munn has managed the shift to a rollator, scooter, and other assistive devices that help her live a better ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

A grant from the ALS Association will fund an early-stage clinical trial to test Tiziana's foralumab nasal spray in 20 ALS ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

The world's largest ALS patient-derived stem cell and biodata repository is now available to researchers globally.

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...

Although she did everything possible to learn about ALS, columnist Juliet Taylor says the disease often left her feeling ...